Kabazitaksel Ever Pharma

Cabazitaxel, the active ingredient in Kabazitaksel Ever Pharma, is a Taxane presented as an intravenous solution for intravenous use. It is indicated for the treatment of metastatic castration‑resistant prostate cancer in patients whose disease has progressed after prior chemotherapy. It is administered under medical supervision in specialized oncology units.

GNH USA supplies Kabazitaksel Ever Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to hospitals, pharmacies and clinical trial sites.

Cabazitaxel is a taxane chemotherapy used in the management of advanced prostate cancer, specifically targeting disease that no longer responds to hormonal therapy.

Metastatic castration‑resistant prostate cancer: improves overall survival and disease control in patients who have progressed after prior docetaxel therapy. Second‑line treatment after docetaxel failure: offers an alternative chemotherapy option to extend survival in advanced prostate cancer.

Cabazitaxel may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: low white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Nausea: feeling of sickness often accompanied by vomiting. - Alopecia: hair loss on scalp and body.

Serious or Rare Side Effects: - Febrile neutropenia: fever with neutropenia requiring urgent medical care. - Severe allergic reactions: anaphylaxis or hypersensitivity with rash, swelling, and breathing difficulty. - Pulmonary toxicity: interstitial lung disease or severe breathing problems.

When using Cabazitaxel, clinicians should observe several precautionary measures to minimize risks. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess liver function: evaluate hepatic enzymes before and during treatment due to potential hepatotoxicity. - Evaluate for hypersensitivity: screen patients for prior allergic reactions to taxanes. - Use cautiously in neuropathy: consider dose adjustments for patients with pre‑existing peripheral neuropathy. - Avoid in uncontrolled infection: postpone administration if active severe infection is present. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Cabazitaxel can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce cabazitaxel exposure. - Concurrent use with other myelosuppressive agents: can increase risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel plasma levels and toxicity. - Anticoagulants (e.g., warfarin, DOACs): heightened bleeding risk due to possible platelet effects. - Live vaccines: reduced efficacy and increased infection risk during immunosuppression.